Yasui T, Yamada M, Kinoshita H, Uemura H, Yoneda N, Irahara M, Aono T, Sunahara S, Mito Y, Kurimoto F, Hata K
Department of Obstetrics and Gynecology, School of Medicine, University of Tokushima, Japan.
J Clin Lab Anal. 1999;13(6):266-72. doi: 10.1002/(SICI)1098-2825(1999)13:6<266::AID-JCLA3>3.0.CO;2-#.
We developed a highly sensitive assay for estrone and 17 beta-estradiol in serum. Estrone and 17 beta-estradiol, obtained by solid-phase extraction using a Sep pak tC18 cartridge, were purified by high-performance liquid chromatography (HPLC). Quantitation of estrone and 17 beta-estradiol were carried out by radioimmunoassay. Not insignificantly, this automatic system of extraction and HPLC succeeded in analyzing 80 samples a week. Intra-assay coefficients of variation (CV) for estrone and 17 beta-estradiol ranged from 19.5 to 28.7%, and from 8.5 to 13.7%, respectively. The minimum detectable dose for estrone and 17 beta-estradiol were 1.04 pg/ml and 0.64 pg/ml, respectively. The serum levels of 17 beta-estradiol using our method strongly correlated with those by Gas chromatography mass spectrometry (GC-MS). The serum levels of estrone and 17 beta-estradiol in 154 peri- and postmenopausal women were estimated to be between 15 and 27 pg/ml and between 3.5 and 24.0 pg/ml, respectively, while the serum level of 17 beta-estradiol in postmenopausal women, in particular, was estimated to be from 3.5 to 6.3 pg/ml. For postmenopausal women who suffered from vasomotor symptoms, the mean levels of estrone and 17 beta-estradiol at 12 to 18 hours after treatment with daily 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) were 135.0 and 21.3 pg/ml at 12 months, respectively. On the other hand, levels of estrone and 17 beta-estradiol at 12 to 18 hours after treatment with CEE and MPA every other day, were 73.4 and 15.3 pg/ml, respectively. These highly sensitive assays for estrone and 17 beta-estradiol are useful in measuring low levels of estrogen in postmenopausal women, and monitoring estrogen levels in women receiving CEE as hormone replacement therapy.
我们开发了一种用于测定血清中雌酮和17β-雌二醇的高灵敏度检测方法。通过使用Sep pak tC18柱进行固相萃取获得的雌酮和17β-雌二醇，经高效液相色谱（HPLC）纯化。雌酮和17β-雌二醇的定量通过放射免疫测定法进行。值得注意的是，这种自动萃取和HPLC系统成功实现了每周分析80个样本。雌酮和17β-雌二醇的批内变异系数（CV）分别为19.5%至28.7%和8.5%至13.7%。雌酮和17β-雌二醇的最低检测剂量分别为1.04 pg/ml和0.64 pg/ml。使用我们的方法测得的17β-雌二醇血清水平与气相色谱-质谱联用（GC-MS）法测得的结果高度相关。154名围绝经期和绝经后妇女的血清雌酮水平估计在15至27 pg/ml之间，17β-雌二醇水平估计在3.5至24.0 pg/ml之间，而绝经后妇女的17β-雌二醇血清水平尤其估计在3.5至6.3 pg/ml之间。对于患有血管舒缩症状的绝经后妇女，每天服用0.625 mg结合马雌激素（CEE）和2.5 mg醋酸甲羟孕酮（MPA）治疗12个月后，12至18小时时雌酮和17β-雌二醇的平均水平分别为135.0 pg/ml和21.3 pg/ml。另一方面，隔天服用CEE和MPA治疗12至18小时时，雌酮和17β-雌二醇水平分别为73.4 pg/ml和15.3 pg/ml。这些针对雌酮和17β-雌二醇的高灵敏度检测方法，对于测量绝经后妇女的低雌激素水平以及监测接受CEE作为激素替代疗法的妇女的雌激素水平很有用。
